Myristicin

Myristicine is an orally bioavailable serotonin receptor antagonist and weak monoamine oxidase (MAO) inhibitor. Myristicine also exerts anti-cancer effects on gastric cancer cells by inhibiting the EGFR/ERK signaling pathway. Myristicine is the main component of nutmeg essential oil and has anti-cancer, anti-proliferative, antibacterial, anti-inflammatory and apoptosis-inducing effects. Myristicine abuse can produce hallucinogenic effects, organ damage, etc^[1][2][3][4]. In Vitro:Myristicin (7.8-31.25 μM; 48 h) can delay the proliferation of gastric cancer cells and induce endoplasmic reticulum (ER) stress and apoptosis; at the same time, Myristicin reduces the expression of cell cycle proteins, increases the expression of Bax, and activates caspase enzyme, and enhances the release of cytochrome C and mitochondrial ROS levels ^[3].
In Vivo:In animal models, Myristicin can inhibit the growth of gastric cancer cells and the EGFR/ERK signaling pathway^[3].
Myristicin (200 mg/kg; po; single dose) treated 6 hours in advance, on acetic acid (AA)-induced small Mouse experimental colitis model has preventive and protective effect^[4].